Loading…
Reported covered position: Congressional Intern, Staff Assistant, Press Assistant
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2026 · third_quarter · Q3
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2026 · second_quarter · Q2
Source: Senate LDA
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2026 · first_quarter · Q1
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2025 · fourth_quarter · Q4
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2025 · third_quarter · Q3
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2025 · second_quarter · Q2
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2025 · first_quarter · Q1
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2024 · fourth_quarter · Q4
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2024 · third_quarter · Q3
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2024 · second_quarter · Q2
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE